This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Melinta Therapeutics, Inc.
Drug Names(s): RX-3341
Description: Delafloxacin is a potent, dual-targeting IV and oral next generation fluoroquinolone antibiotic providing broad-spectrum coverage, including MRSA, to treat resistant hospital-based infections. Captisol, licensed from Ligand, is used in the formation of delafloxacin. The compound has been shown to be at least 16-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of <= 0.5 ug/ml for delafloxacin versus > 16 ug/ml for all other quinolones). The oral formulation was tested in CAP and bronchitis while the IV formulation has been tested in cSSSI.
Rib-X Pharmaceuticals and Ligand
In 2008, Rib-X Pharmaceuticals and Ligand entered into a development and commercialization agreement for the use of Captisol, a propriety modified cyclodextrin, in the formation of delafloxacin. Rib-X Pharmaceuticals change its name to Melinta Therapeutics.
Melinta and Euroframa
In January 2015, Melinta Therapeutics and Eurofarma Laboratrios entered into commercialization and distribution agreements for delafloxacin. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta will receive a combined upfront cash and equity payment of $15 million, as well as milestones and royalties on future sales of delafloxacin.
Additional information available to subscribers only: